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vForeword
As the national membership organisation for the drug field, it is part of 
DrugScope’s remit to speak to the media about drugs and drug use, as well as 
to engage in dialogue and discussion around policy responses to these issues. 
One of our key aims is to raise public awareness and understanding around 
drug misuse, while informing the debate about drugs and drug policy. 
For this reason, our spokespeople were busy in October 2007 when something 
of a media firestorm was ignited. A BBC report revealed that only 3 per cent of 
drug users had left drug treatment free of all drugs (including methadone) in 
2006/07. 
Subsequent press coverage was typical of much media reporting on drug 
treatment. The language was one of ‘failure’, of a ‘waste of taxpayers’ money’ 
and of ‘junkies’ failing to quit their habits. The real people behind the numbers 
and their stories were largely unreported – those whose lives had been 
improved by drug treatment, but also those who felt that the system had let 
them down.
It is sometimes too easy to lay ‘blame’ at the media’s door. While we are all 
aware that coverage of drugs and drug issues is frequently exaggerated, 
sensationalised or agenda-driven, we also have to acknowledge that the media 
rarely works in a vacuum. Without being fuelled by, or anchored to, a quote 
from an ‘expert’, politician or group of some sort, negative or hostile coverage 
usually fails to gain traction. In October 2007, all three weighed in. 
The BBC report provided a catalyst for something which had been coming for 
some time. The fire took hold precisely because there was a debate developing 
in and around the drug field about treatment effectiveness, value for money 
and approach. Many critics of the system shared the view that there was too 
much focus on ‘harm reduction’ or ‘stabilisation’ at the expense of ‘abstinence-
based’ interventions. More broadly, there was growing support for the view that 
we needed to be more ambitious for people in treatment.
With the effects of the media coverage still being felt, we decided to bring 
people together to discuss and debate drug treatment. We wanted to hear 
from people with different viewpoints and opinions, different philosophical and 
ideological standpoints – but people who also shared experience, knowledge 
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and a passionate desire to make things better. The lines for The Great Debate 
events held in 2008 were drawn.
Drug treatment at the crossroads is a distillation of the many voices and 
opinions heard at the events we held in Edinburgh, Manchester and London. 
Naturally, there was disagreement, but also a surprising degree of consensus 
between participants – not least the agreement that drug treatment deserves 
support and investment. And we are encouraged to learn that this belief in 
the importance of drug treatment is shared by the public. Over three quarters 
(76 per cent) of the people who responded to an ICM/DrugScope survey 
(February 2009) agreed that drug treatment is a sensible use of government 
money, so long as it benefits individuals, families and communities. This is 
an important and significant endorsement for investment in a system that 
benefits a stigmatised and marginalised group, at a time of straitened financial 
circumstances. 
It is crucial that we stand up for drug treatment. There are many successes, 
of which those working in the sector can and should be proud. But we must 
ensure that open debate, informed criticism and, yes, expressions of passion, 
are not silenced or closed down. We must also recognise that the ultimate 
accolades must go to those drug users (and their families and friends) who have 
taken steps to improve not just their lives, but also those of their communities. 
Drug treatment at the crossroads is about making the case for drug treatment 
and looking ahead to where we go next. It is also about ensuring that – 
working together – we have the necessary commitment, the tools and the 
vision, to make drug treatment in this country even better.
Martin Barnes
Chief Executive
DrugScope
February 2009
1In spring 2008, DrugScope hosted a series of seminars on the future of drug 
treatment. The Great Debate gathered together DrugScope members, along 
with other experts and stakeholders with direct experience of drug treatment, 
representing a range of different views and treatment philosophies. The object 
was to debate the results and prospects of drug treatment, and to inform and 
shape the wider public and political debate, at a time when sections of the 
media and some politicians were publicly claiming that the treatment system 
was failing. 
Key facts about drug treatment
1 The last decade has seen a substantial rise in the number of individuals 
in contact with drug treatment services. In 1998/99 there were 85,000 
clients engaged with treatment providers but ten years later this level had risen 
to almost 203,000. This represents an increase of about 238%.
2 Funding for drug treatment has increased over recent years, but 
now looks likely to level off. Funding for drug treatment is provided by 
government via the Pooled Treatment Budget (PTB), combining monies from the 
Home Office and the Department of Health. The PTB rose from £142 million 
in 2001/02 to £396 million in 2007/08. The 2009/10 budget stands at £406 
million. However, the numbers of clients in treatment is also increasing year 
on year. Despite the welcome investment in drug treatment, in real terms the 
amount of money available to spend per client has been decreasing each year.
3 As a service user accessing drug treatment in the UK, you are more 
likely to be prescribed a substitute drug such as methadone than you 
are to receive treatment in a residential rehabilitation centre. In 2007/08, 
National Drug Treatment Monitoring System (NDTMS) data on treatment 
modalities shows that 131,110 people received substitute prescribing treatment. 
During the same period, 5,350 people received PTB-funded treatment in 
residential rehabilitation centres. 
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4 In recent years, the numbers of individuals discharged from treatment 
‘drug-free’, meaning free of all drugs including legally prescribed 
opiate substitutes such as methadone or buprenorphine, has increased. 
However, it is the case that the number of individuals leaving treatment ‘drug-
free’ remains low as a percentage of the total number of people engaged with 
treatment.
Key messages
Despite the different perspectives of participants, there was a high degree of 
consensus on a range of key issues.
1 Drug treatment is important. There is clear evidence of the benefits of drug 
treatment for individuals, families, communities and society and it should 
remain a priority for public investment.
2 Choice in treatment should be promoted. Drug treatment services should 
support both harm reduction and abstinence-based approaches. Methadone 
and other substitute drugs have a role in drug treatment, but services must 
also work with people on methadone prescriptions to help them (re)build their 
lives and move on in their recovery. Abstinence is a desirable outcome, but only 
where it is realistic and safely achievable. 
3 The system must put people first. Care pathways out of dependency must 
be more individualised, and that means putting service users at the centre. 
4 Relationships matter. As recognised in other fields, such as mental health, the 
values, competencies and attitudes of staff working in drug services can be as 
important as the particular intervention they are delivering.
5 We should all be aiming higher. There is strong support for the increased 
emphasis on ‘recovery’ and ‘social (re)integration’. Care pathways out of 
addiction are about a lot more than drug treatment. The emergence of recovery 
as a key concept for the drug sector provides an opportunity to address issues 
like housing and access to employment. But there are also risks, and it is 
important to recognise the formidable barriers that stand between many people 
in drug treatment services and a decent quality of life. 
6 Families and communities need support too. Drug treatment and the road 
to recovery are not only the business of specialist services. Families, friends, 
neighbourhoods and communities are a vital source of recovery capital, 
but have often been at the margins of debate about drug policy and drug 
treatment. 
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Conclusion
There are certainly disagreements and differences of approach among 
people involved in the development and delivery of drug treatment services. 
At the same time, there is a wide area of consensus and the contours of a 
reinvigorated and enriched drug policy paradigm were discernible at The Great 
Debate meetings. 
There was unanimous support for continued government investment in drug 
treatment, with some of the biggest critics of current policy, from both ‘harm 
reduction’ and ‘abstinence’ perspectives, arguing for greater investment, not 
less. 
Overwhelmingly, it was agreed that we have made progress in improving access 
to drug treatment in Britain, and that this has delivered real benefits for the 
community in terms of health and well-being, social policy and crime reduction. 
The question is about how we move forward from here. Solid achievements 
could be lost, if respect for clinical judgement and evidence-based service 
provision is overridden by a dogmatic and ideological approach. 
Recommendations
The following recommendations were not discussed during The Great Debate 
events, but have been shaped by them.
reshaping the Debate
1 Politicians from all parties should publicly commit to an evidence-
based approach to drug policy. The advice of independent experts must be 
respected. 
2 The Government should fund, develop and implement a 
communications strategy to inform the public about the achievements 
of front-line drug services. There is an urgent need to address negative 
attitudes and discrimination against people who are in or who have been in 
drug treatment. 
rights anD choices
3 Drug treatment services must address diversity issues more effectively. 
The EHRC and the NTA should work together to improve the responsiveness of 
drug treatment services to race, ethnicity, culture, religion, gender, sexuality, age 
and disability. 
4 Drug treatment should be provided in accordance with the new NHS 
Constitution. This means that every service user entering drug treatment 
should be provided with a statement of their rights and responsibilities. 
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5 Drug service users should be involved in decisions about their 
treatment. Every drug user entering the drug treatment system should have an 
effective and comprehensive care plan which should be regularly reviewed with 
a designated key worker. Service users must also receive clear and unbiased 
information about available treatment alternatives.
6 There should be further research on alternatives to substitute 
prescribing. Psycho-therapeutic, psycho-social and abstinence-based 
approaches should all be investigated along with options for the treatment for a 
wider range of drug problems. 
7 There should be further work to reduce drug-related deaths. Abstinence-
based services (including services in prisons) should be required to have robust 
policies for managing relapse and the associated risks, particularly overdose. 
Working together to improve outcomes
8 All local drug partnerships need to develop effective partnerships with 
other local agencies. These would include JobCentre Plus, housing providers 
and mental health services. 
9 There should be clear recognition of the contribution of families, carers 
and other support networks to recovery. Better support should be available 
to them (including appropriate financial support). 
10 The next round of the Comprehensive Spending Review should 
introduce treatment outcome targets that include re-integration. For 
example, we should be increasing the numbers of drug users moving into 
quality housing or education, training and employment, as a key policy priority.
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“There is a fundamental debate taking place out 
there about our work and our values. We need 
to lift our heads up from technical discussion and 
defend our right to develop philosophies of care 
which are about shaping recovery…
“Is it fair to say our field is in crisis at this point 
in time? Unfortunately, I believe it is. I believe 
this is because of two things. First, I think we are 
divided within. Second, increasingly there are 
attacks on drug treatment from outside – and 
these are becoming more virulent, sustained and 
widespread.”
Ian Wardle, Chief Executive, Lifeline, The Great Debate, Manchester
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In spring 2008, DrugScope hosted a series of seminars to debate the future of 
drug treatment services in the UK.
The Great Debate kicked off in Edinburgh in April and culminated with a session 
of the All Party Parliamentary Drug Misuse Group in the Palace of Westminster 
on 1 July. Along the way it took in debates in Manchester, Birkbeck College, 
London and the 2008 Drugs and Alcohol Today Conference at Islington Business 
Design Centre, London.
Among the speakers were influential contributors to recent debate about 
drug treatment, including Professor Neil McKeganey (Centre for Drug Misuse 
Research, University of Glasgow) and Mike Ashton (editor of Drug and Alcohol 
Findings). It was Mike Ashton’s article ‘The New Abstentionists’, published 
in Druglink in December 2007, that helped to frame The Great Debate. 
Participants included service users, carers, drug treatment providers, managers, 
commissioners, GPs and other health service professionals, providers of 
related services, academics, policy makers and others. Many were members of 
DrugScope, which is the national membership organisation for hundreds of 
service providers, managers and commissioners across the UK.
The result was a series of rich, nuanced and constructive debates. By bringing 
together the testimony of experts involved in drug treatment in a whole 
variety of ways, this report seeks to scope out the contours and parameters for 
constructive and informed public debate about drug treatment.
While there were areas of disagreement, there was a high degree of consensus 
among participants on three key issues:
1	There was broad consensus on the importance of continuing to improve 
drug treatment services, and agreement that this should remain a key 
priority area for public investment. Public spending on drug treatment is the 
right thing to do for a society that is committed to providing routes into society 
for some of the most excluded and marginalised. It is also highly cost effective 
and delivers substantial economic and social benefits for taxpayers. There were, 
however, areas of disagreement on how this money should be spent in future 
and what the priorities should be in continuing to support and develop drug 
treatment provision.
1.1
“Drug treatment is such 
a large and complex 
issue, it sometimes 
seems the only way 
that we can get our 
heads around it is 
by shrinking it. But 
in the process of 
shrinking it we reduce 
its complexity, and by 
reducing its complexity 
we reduce our impact 
on the thing that we’re 
thinking about, because 
we’ve over-simplified 
it. The model that we 
use to think about a 
problem shapes our 
outcomes.”
Peter McDermott, Policy 
and Press Officer, The 
Alliance, and Non-Executive 
Director of the NTA, The 
Great Debate, Manchester
introDuction
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2	There was widespread concern that public debate about drugs was 
becoming increasingly and unhelpfully polarised. The large majority of 
participants believed both that there had been significant strides forward in 
drug treatment in recent years and that services can work better still.
3	There was agreement on the need to recognise the complexity of drugs 
as an issue and the complex needs of many people who walk through 
the doors of drug services. There was agreement on the value of a more 
holistic and individualised conception of the recovery journeys of individuals 
with drug problems, as services work with them to rebuild often chronically 
damaged lives.
Many contributors also commented on the need to engage with a wider public 
on drugs and drug treatment; to avoid the jargon and technicality that make for 
narrow and inward-looking discussion, missing the bigger picture and dodging 
the fundamental issues; to correct inaccurate and stigmatising portrayals of 
drug service users, that can feed unhelpful and inhumane policy; to inform 
people about the work, and to persuade people of the value, of the drug 
treatment services that are operating in their communities.
It is hoped this report can make a contribution to this broader public debate.
“i am asking you questions and you can’t give me straight answers 
– and you say the media is giving a very negative image of what 
goes on in the drugs field. Well, how on earth do you expect lay 
people to be sympathetic, to be supportive, to be caring, when 
you’re not communicating with them? i don’t know what you are 
about or where you are going with this.”
Journalist speaking from the floor, The Great Debate, Edinburgh
“of course the general public do not on the whole understand 
that maintenance is a positive intervention and of course they 
think the ideal is getting people off drugs and away from 
addiction altogether. that’s because largely we don’t ever bother 
explaining it. We have become so concerned to convince people 
to invest on the basis of fear, we seem to have forgotten how to 
ask them to invest on the basis of compassion.”
Sara McGrail, Freelance Drug Policy Specialist, The Great Debate, London 
(Birkbeck) 
The full text of Sara’s contribution to the debate can be found at  
www.saramcgrail.co.uk
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The background
It is no coincidence that this series of debates occurred when it did – in 
spring 2008 – or that The Great Debate events at that time attracted sizeable 
audiences of people from diverse backgrounds, who were animated and 
passionate in their discussion of the issues. A lot had been going on, and there 
was a lot to talk about.
Specifically, the background to The Great Debate was provided by three – 
closely related – developments. Firstly, the rise in 2007 of what has been 
labelled ‘New Abstentionism’. Secondly, a growing interest in the concepts 
of ‘recovery’ and ‘social (re)integration’. Thirdly, the expectation of shrinking 
resources.
New Abstentionism
When the NTA published its Annual Report 2007–08, it was able to report 
that 202,000 people accessed drug treatment that year. This represented 138 
per cent of the original target for the NTA; the average wait for treatment to 
start was down to a week. By and large, drug services were retaining people in 
treatment for 12 weeks or more, defined as the minimum period for treatment 
to be effective; 77 per cent of people who commenced drug treatment in 
2007–08 were retained for 12 weeks or longer.1
The question that remained to be answered – as the NTA itself had recognised 
in its Annual Report the previous year – was about the quality of treatment 
and about the outcomes that services are actually delivering for service users, 
families and carers, neighbourhoods and communities. Retention is a reasonable 
proxy measure for some of this, because the evidence base shows that the 
longer you keep people in treatment, the better the outcomes are likely to be. 
But it is no guarantee of good outcomes.
The opening lines of Mike Ashton’s article, ‘The New Abstentionists’, takes 
up the story: “Towards the end of October 2007 the NTA’s crime-reduction 
justification for investing in treatment wilted before the BBC’s straightforward 
1 national treatment agency (october 2008), Effective treatment, changing lives – Annual Report 
2007 – 8, p. 5 (http://www.nta.nhs.uk/publications/publications.aspx?categoryiD=34) 
1.2
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assumption that treating addiction ought to be about getting people off drugs. 
It was an emperor’s clothes moment from which the NTA took time to recover 
… Their own figures showed that in England at the end of 2006–07, just 3 per 
cent of people in drug treatment that year were recorded as having completed 
it and left drug-free.”2
“In some ways,” Mike Ashton concluded, “the BBC’s intervention was a 
welcome return to forefronting what I’d guess most people think treatment 
should be about”3 – a view that was being championed politically by the 
Conservative Party’s Social Justice Policy Group.4
In other ways, however, the impact has been unhelpful and has not led to 
rational and informed debate about drugs and drug treatment. The BBC’s 
report led to blanket – and highly misleading – claims that the drug system 
was ‘failing’. The Daily Mail complained on 31 October 2007 of a “£1.9 million 
bill to help just one drug addict kick the habit,” while The Sun declared that 
the “NHS blows £130 million curing 70 junkies” – both these reports viewed 
anything other than complete abstinence (including abstinence from substitute 
drugs like methadone) as failure.
David Davis MP, then the Shadow Home Secretary, was prompted by the BBC 
coverage of the NTA figures to write to the Chair of the House of Commons 
Public Accounts Committee asking for an investigation into drug treatment. 
He described public investment in treatment as “massive failed expenditure”, 
commenting: “this is an absolutely shocking revelation which speaks volumes 
about the Government’s incompetence and distorted priorities. It is yet more 
evidence why we should focus spending on getting addicts off drugs, and not 
just spend money managing their addictions.”5
It is entirely legitimate to raise questions about the use of substitute drugs like 
methadone. It is worrying, however, when the media and politicians enter into 
what are essentially clinical debates in ways that misrepresent the facts and 
politicise treatment options. The public should be presented with the full facts:
The use of methadone and buprenorphine as treatments for opiate 
dependency is recommended by the National Institute for Clinical 
Excellence (NICE). It is unusual to find broadcasters, newspapers and 
politicians attacking a statutory health authority like the NTA for operating 
within clinical guidelines, or to characterise NICE recommended treatment for 
2 mike ashton (2008), ‘the new abstentionists’, Druglink insert, Jan/Feb 2008, Drugscope  
(www.drugscope.org.uk/Documents/pDF/good%20practice/newabstentionists.pdf). 
3 Ibid. 
4 centre for social Justice, addiction Working group (December 2006), The State of the Nation 
Report – Addicted Britain (at http://www.centreforsocialjustice.org.uk/default.asp?pageref=192)
5 more recent media stories about prisoners who were refused methadone and effectively subject 
to forced detox in the prison system have prompted similar responses. When these prisoners 
were awarded damages of around £4,000 each for a breach of their human rights, one senior 
opposition politician commented in The Daily Mail that “it is a breach of no-one’s rights, let 
alone prisoners, to be denied drugs to help sustain their illegal habit.” The Sun quoted mark 
Wallace, a spokesman for the taxpayers’ alliance, who declared that it was “disgusting that law 
abiding taxpayers had to stump up because addicts weren’t allowed to take drugs in prison.” 
a year later – in november 2008 – The Sun in scotland was declaring “£26 million – that’s what 
you pay per year to keep junkies on methadone.”
“The purpose of this 
debate is to ensure 
that the voices of 
people with experience 
of drug services – as 
service users, carers, 
providers, managers 
or whatever – are 
heard, as well as 
those of politicians 
and journalists. The 
purpose is to help 
people to come to an 
understanding of what 
is meant by recovery, 
re-integration and 
abstinence – all these 
words that are around 
at the moment.
What are the 
opportunities and risks 
of rebalancing the 
discussion in this way? 
Why is this shift in the 
debate happening, 
and why now? What 
is the political – and 
perhaps the financial 
or economic – 
background? […] What 
kind of evidence is 
there to feed into the 
discussion? How do we 
improve quality? What 
are the implications of 
all this for real services 
– for service users and 
communities?”
Professor Susanne 
McGregor 
London School of Hygiene 
and Tropical Medicine 
Chair, The Great Debate, 
Manchester
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drug dependency as simply a way of helping drug addicts to ‘sustain’ their 
‘addictions’. It is also unusual for a report from a health authority that shows 
that it has exceeded its performance targets, increased treatment capacity and 
slashed waiting times to be described as a complete failure of the system. There 
are grounds for some concerns but there is also a need for a recognition of 
substantial progress and a sense of perspective.
The public are not being presented with the full picture on the costs and 
benefits of investment in drug treatment. There is abundant evidence that 
investment in drug treatment is an effective way of reducing overall expenditure 
of taxpayers’ money, because of its impact on criminal justice, health and other 
social costs. Moreover, as the Centre for Social Justice report makes clear, a 
more abstinence-focussed treatment system would require more public money 
for treatment, and not less. No one involved on any side in The Great Debate 
wants to see people left to cope without good quality and evidence based 
treatment, or doubts that this would be both unethical and a health and social 
policy disaster.
All this said, isn’t it simply obvious that the purpose of the drug treatment 
system should be to get people off drugs – including substitute drugs?
What about people who are not able to achieve abstinence – at least, not yet? 
What about people who achieve abstinence for a while, but relapse when 
things start to go wrong in their lives? What about people who simply can’t 
face the abuse and trauma that has scarred their lives without using drugs, 
unless they have access to intensive psychological support? Or who can’t get 
it together until they’ve somewhere to live and something else to live for? 
What about people who succeed in reducing their drug use or switching to 
less harmful drugs, but not in getting off drugs completely? What about the 
tens of thousands of people who have begun to rebuild their lives, to end their 
dependence on illegal drug markets and/or to move on from criminal lifestyles, 
by using substitute drugs like methadone and buprenorphine?
“sooner or later we are going to have to provide services that 
are focussed on getting addicts off drugs, even if the treatment 
industry does not really rate that as a goal.”
Professor Neil McKeganey, Centre for Drug Misuse Research, University of 
Glasgow, The Great Debate, Edinburgh
“radical … reform of treatment is needed towards holistic and 
abstinence-based approaches. it is about facing the fact that 
abstinence is the most effective method of treatment and the 
only appropriate one for many addictions.”
Social Justice Policy Group (Chairman: Rt Hon Iain Duncan Smith MP), 
Breakthrough Britain, Volume 4 – Addictions, Policy Recommendations to the 
Conservative Party, July 2007
the backgrounD
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‘Recovery’
Another obvious way of assessing the quality of outcomes that the drug 
treatment system is delivering for its clients and the wider community is to look 
at the sorts of lives it is supporting people who have experienced drug problems 
to build or re-build.
How effectively is the drug treatment system working with other key agencies 
to secure decent and stable accommodation for clients who have nowhere to 
live? What about their general health and well-being? Is it supporting people 
to put relationships back together and rebuild family support networks? How 
many people who enter drug treatment services with skills gaps, and/or who are 
unemployed, are being helped into education, training or work?
The term ‘recovery’ was very much the buzz word coming into The Great 
Debate in spring 2008. It is often used to describe a vision and vocation for 
drug treatment that is less fixated on clinical indicators and quantitive targets, 
and more concerned with ‘social’ (re)integration and qualitative outcomes.
“What do we mean by recovery? We mean a process through 
which an individual is enabled to move on from their problem 
drug use, towards a drug-free life as an active and contributing 
member of society. Furthermore, it incorporates the principle 
that recovery is most effective when service users’ needs and 
aspirations are placed at the centre of their care and treatment. in 
short, an aspirational, person-centred process.”
The road to recovery: A new approach to tackling Scotland’s Drug Problem, The 
Scottish Government, May 2008
“the goal of all treatment is for drug users to achieve abstinence 
from their drug – or drugs – of dependency. For some, this can 
be achieved immediately, but many others will need a period of 
drug-assisted treatment with prescribed medication first. Drug 
users receiving drug-assisted treatment should experience a rapid 
improvement in their overall health and their ability to work, 
participate in training or support their families.”
Developing new approaches to drug treatment and social integration 
Drugs: Protecting Families and Communities – The 2008 Drug Strategy, Home 
Office 2008
“the process of recovery from problematic substance use is 
characterised by voluntarily-sustained control over substance use 
which maximises health and well-being and participation in the 
rights, roles and responsibilities of society.”
UK Drug Policy Commission, Consensus statement on recovery, 2008
Drug treatment at the crossroaDs
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“in scotland, they’ve found that if you pitch an uncompromising 
and virulent abstentionist lobby against a passionate and 
committed harm reductionism, you’ve got a recipe for an 
argument with the potential to go on for ever and ever. they’re 
now trying to break that deadlock by taking on board what they 
call ‘the philosophy of recovery’ and hoping that both can find 
some common ground there.”
Ian Wardle, Chief Executive, Lifeline, The Great Debate, Manchester
Money
The major expansion of treatment highlighted by the NTA in its 2006–07 report 
has been made possible by significant increases in spending over the past 
ten years. The NTA calculates that in 2007–08 the total expenditure on drug 
treatment, excluding prison-based treatment, was £597 million.6 Cost benefit 
claims have been made for drug treatment, with the Home Office website 
currently citing NTORS research that claims that for every £1 invested in drug 
treatment, at least £9.50 is saved in criminal justice and health costs.
But will investment continue at these levels in more straitened economic and 
financial circumstances?
There is a sense in which investment is falling already. While the overall spend 
on treatment has more than doubled since 2001–02, there has also been a 
huge expansion in the numbers of people entering treatment. The spend per 
service user has been falling year-on-year since 2002. The Government has 
now announced a standstill in the absolute level of central funding until 2011, 
requiring ‘efficiency savings’ of £50 million a year.
With economic pressures threatening to squeeze public spending, it is easy to 
envisage a further contraction in investment in drug treatment.
“[the] pooled treatment budget … will stay static over the next 
three years and that is a very significant challenge. but remember, 
although it will stay static over the next three years, in 2000/2001, 
central government support for drug treatment was sixty million. 
this year, it’s four hundred million. the reason we believe we can 
meet these challenges, with a flat budget, is because so much 
money has already been pumped into the system, we believe we 
can drive enough efficiencies to deliver this challenging agenda.”
Paul Hayes, CEO National Treatment Agency, NTA National Conference 2008
6 national treatment agency (april 2008), Better treatment, better outcomes – Annual Report 
2006–07, p. 4–5 
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“When we get better, drug treatment 
services like to take the credit and when 
we get worse they like to give us the 
blame. And my experience is that we’re 
exactly the opposite way around.”
Peter McDermott, Service User, Policy and Press Officer, The 
Alliance; Non-Executive Director of the NTA, The Great Debate, 
Manchester
“If you are under attack, form a circle, but 
remember to shoot outwards.”
Professor Susanne McGregor, London School of Hygiene and 
Tropical Medicine, Chair, The Great Debate, Manchester
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Methadone and other substitute drugs have a role in 
drug treatment, but services are too ready to ‘park’ 
people on methadone.
Methadone and the 
parking problem
Intervention from floor: “Does peter mcDermott really think he is 
on a recovery path using methadone every day?”
Peter McDermott: “yes, i absolutely do. i see it as no different 
to someone using insulin to manage diabetes. For me recovery 
is any change in a direction that can improve the quality of your 
life … that is a recovery path. any path that moves people away 
from chaos, discomfort and the miseries that a chaotic drug user 
can experience, to any point that is an improvement on that … is 
recovery as far as i’m concerned.”
Floor speaker: “Well, […]for nearly 20 years i was a service user 
who was using methadone. i’d been a chaotic user and a career 
criminal. they said i’d never come off methadone, but i have 
and i feel recovery is now real for me for the first time. Why are 
treatment services allowed to tell people that they’ll never be 
able to come off methadone? i think it is disgusting. everyone 
should be offered the full range of options. For 19 years i thought 
i needed to take methadone every day … but, you know what? it 
wasn’t true … i now know it was a lie.”
Peter McDermott: “but denying methadone patients the status 
of recovery is really stigmatising. We’ve recruited over a hundred 
thousand people into methadone. if we now abandon them 
to some second class status within the recovery movement, 
that is unacceptable … [i]t is morally unacceptable for the drug 
treatment field. and i’m speaking as someone who is really quite 
excited by the rigour and obvious strength of recovery networks. 
i think their contribution to the field is absolutely seminal in 
shifting our opinions and demanding we raise our game in the 
variety of what we offer, but we absolutely cannot and must not 
abandon people who are on opiate substitute treatment ….  
[t]hey’re already second class citizens in our society and if, as a 
result of the change in direction we take we further relegate 
them, then we are doing them a double disservice.”
2.1
methaDone anD the parking problem
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There has been particular concern about the widespread use of substitute 
drugs, particularly methadone (the other main substitutes used are Subutex, or 
buprenorphine, but methadone is much more widespread).
Methadone is a synthetic opioid, which is used to prevent people from 
experiencing withdrawal effects from heroin and other opiate drugs. It has long 
duration effects and does not provide the same ‘high’ or ‘rush’ as drugs like 
heroin. This means that it can help to stabilise lives, prevent drug withdrawal 
and end (or meliorate) reliance on illegal drug markets, with the associated 
costs and risks. Some service users say that the doses of methadone they are 
given are not sufficient to prevent withdrawal and discomfort. Many experience 
unpleasant side effects, including nausea, constipation, weight gain, dental 
decay, insomnia, impotency, blurred vision and depression. However, many are 
positive about the impact that methadone has had on their lives, and the role it 
has played in their recovery.
Sometimes people prescribed methadone will also be using street drugs. At 
Manchester, the parent of a long-term heroin user complained that her experience 
was that many drug users were “using methadone as a top up when they can’t 
get heroin.” Peter McDermott said that he had continued to use other drugs 
when initially prescribed methadone. He saw methadone as something that could 
“make my life a bit easier and take away the pressure to score street drugs all the 
time.” By initiating engagement with drug services, it pushed him into “a form of 
recovery” – within five years he was “no longer using illegal drugs at all.”
Why the concerns about the treatment system’s reliance on methadone?
An NTA audit of prescribing in England was published in June 2006 based on 
242 returns to a questionnaire sent to specialist drug services in 2005. These 
services engaged a total of 51,482 clients, of whom 38,335 (74.5 per cent) 
were prescribed opioids as part of their treatment. The majority – 30,901 clients 
– were prescribed methadone. The audit revealed a sharp and substantial rise 
in methadone and other substitute prescribing, although it noted that this was 
during a period when the overall numbers in treatment increased sharply.1
There are concerns that services are over-dependent on methadone. There 
is a particular concern about the use of methadone not simply to stabilise 
people’s lives while other interventions kick in, but over many years (so-called 
‘methadone maintenance’).
Key messages on methadone
MESSAGE 1 There is a strong evidence base for substitute prescribing, but that may 
be partly because more has been invested in researching it. In a Technical 
Appraisal published in January 2007, NICE recommends both methadone and 
buprenorphine as treatments for people with opioid dependencies.2 It was 
1 David best and angela campbell (June 2006), Summary of the NTA’s National Prescribing Audit, 
research briefing 19, national treatment agency. 
2 national institute of clinical excellence (2007), Methadone and buprenorphine for managing 
opioid dependence – technical appraisal (ta114) at www.nice.org.uk/guidance/ta114
“If you are asking 
people who can just 
about walk to run a 
marathon, don’t be 
surprised if some of 
them perish in the hot 
sands … [W]e must be 
very careful … because 
there is no doubt that 
the research over 45 
years says exactly the 
same thing – every 
country, every model: 
it says drug use 
reduces when you give 
somebody a substitute 
– it says that mortality 
improves, morbidity 
improves, people’s 
lives are healthier and 
they are more likely to 
engage.”
Speaker from the floor, The 
Great Debate, Manchester
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argued by some Great Debate participants that a big investment in research on 
substitute prescribing itself reflected (and reinforced) a medicalised approach to 
drug treatment.
“if there is not as much evidence for interventions other than 
methadone maintenance, this may well be because of a lack of 
rigorous inquiry, rather than because these interventions are not 
actually effective.”
Paolo Pertica, Head of Blackpool Community Safety and Drug Partnership, 
The Great Debate, Manchester 
MESSAGE 2 We need to acknowledge the progress people can make on substitute 
drugs. We need measures that can capture the progress towards recovery of 
people who are still on substitute drugs.
“the most pressing challenge … is that while on methadone or 
any substitute drug, users describe how they felt more together 
in themselves, but were not perceived this way by other people. 
they had made a big change. but the perception of those around 
them – including peers, family, community, media and some 
workers – was that they were still ‘junkies’; they had merely 
changed their addiction from illicit drugs to legally prescribed 
ones.”
Jason Wallace, Service User, Scottish Drugs Forum, The Great Debate, 
Edinburgh
“my concern … is that […] the emphasis on treatment 
completions and treatment exits will mean that all those people 
who successfully make progress on recovery while remaining 
on methadone and in treatment, don’t show up as having been 
helped – it would be nice to come up with a way to count those 
successes as well.”
Speaker from the floor, The Great Debate, Manchester 
MESSAGE 3 There is a broad consensus that simply ‘parking’ people on methadone is 
not good enough. Giving people methadone does nothing directly to sort out 
other issues in their lives, which often provide the causes and contexts of their 
substance misuse problems.
“Drug treatment – whether it is focused on abstinence or 
maintenance – in and of itself is not going to solve the underlying 
problems that can make drug use problematic. poverty … is not 
methaDone anD the parking problem
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soluble in methadone hydrochloride. nor is a decrepit education 
system, or a lack of challenging and satisfying employment, or a 
shortage of decent housing.”
Sara McGrail, Freelance Drug Policy Specialist, The Great Debate, London 
(Birkbeck)
“there are quite a few people who work in the drug treatment 
system who do see methadone as about control, … who have very 
low expectations [of] and aspirations [for] the people they work 
with ... [and] who do not have faith in the ability of service users 
to make positive changes in their lives.”
Peter McDermott, Policy and Press Officer, The Alliance, and Non-Executive 
Director of the NTA, The Great Debate, Manchester 
MESSAGE 4 ‘Parking’ people on methadone has been encouraged by the crime 
reduction focus of recent drug policy. Methadone can end (or reduce) 
dependence on illegal markets, and therefore the need to raise money to pay 
for drugs – which can be linked to acquisitive offending such as shoplifting and 
theft. By focussing on the drug-crime link, this paradigm has reduced public 
sympathy for service users, and the perception of them as patients who need 
care and support.
“the more our centre of gravity has shifted towards this criminal 
justice ghetto, the more punitive and isolated we have become 
from the hopes and aspirations of the people who use our 
services. We need to take a long hard look at our philosophies 
of care – in particular, we need to raise the question of whether 
our harm reduction philosophies have survived their sustained 
exposure to a criminal justice model.”
Ian Wardle, Chief Executive, Lifeline, The Great Debate, Manchester
“turning up at the cat team once a fortnight, being handed a 
methadone script and going back out the door again … that is 
no use to anybody. effective treatment needs to be substitute 
prescribing hand in hand with other things … effective treatment 
is about community-based programmes where people can sit 
down with a key worker, develop a care plan, look to where they 
want to go and how they are going to achieve it, and regularly 
reviewing that care plan – substitute prescribing has a role in all 
this, but it is not a substitute for it.”
Service user and volunteer with the Scottish Drugs Forum, The Great Debate, 
Edinburgh
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There was wide agreement at The Great Debate  
that abstinence is a desirable outcome, but only where 
it is realistic and safely achievable – often it is not  
(at least, not yet).
Being sensible about 
abstinence
 “I have never said that methadone is not suitable for some 
people. It certainly is. But it is not suitable for 22,000 addicts in 
Scotland, because that must be virtually everybody in treatment.”
Professor Neil McKeganey, The Great Debate, Edinburgh
“Detoxification, without all the things that should be going 
with it, is a bit like jumping off a cliff. Some people smash at the 
bottom.”
Mike Ashton, The Great Debate, Edinburgh 
‘Freedom’ from substitute drugs is certainly desirable where achievable. They 
often have unpleasant side-effects, and impose other constraints on people’s 
lives (for example, supervised methadone consumption can make it difficult to 
take up training or employment opportunities).
Many service users say that their aim is to become drug-free. But if this was 
easy to achieve, then drug problems and drug treatment would be a lot more 
straightforward than they actually are. Attempting abstinence prematurely or 
without proper support can undermine confidence, result in a disengagement 
from services, set back recovery and result in significant harms to service users, 
families and carers and the wider community.
In extreme (but, regrettably, not infrequent) cases, drug detoxification without 
proper support is associated with drug-related deaths: if people start using 
drugs again, a loss of tolerance can result in overdose. For example, high rates 
of drug-related deaths among recently released prisoners are often the tragic 
consequence of people returning to opiate use after a period of abstinence or 
reduced consumption.
A recent Probation Circular (PC23/2007) called Reducing the risk of drug-related 
deaths states that newly released male and female drug-using prisoners are 29 
and 69 times more likely, respectively, to die during the first week of release 
from prison compared to their peers in the community. A key risk factor is 
loss of tolerance. It explains that “on release from prison an offender could 
2.2
“Only once someone 
has attained this state 
of grace – ‘abstinence’ 
– are they granted 
assistance with such 
vital tools as education, 
training and housing. 
The view is that 
someone who is still 
‘dirty’ wouldn’t be able 
to make use of such 
things.”
Dr Eliot Ross Albert, 
Director of the UK Harm 
Reduction Alliance and 
founder member of the 
London User Forum, The 
Great Debate, London 
(Birkbeck)
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overdose by using the same amount of the drug that he/she used before they 
went to prison.”1 (It is also explained that methadone-related overdoses among 
recently released prisoners are generally the result of released prisoners buying 
methadone illegally from people in treatment who may have significantly higher 
tolerance levels than them.) There were a total of 1,382 drug-related deaths in 
2005.
Key messages on detox and abstinence
MESSAGE 1 The relationship between detoxification, methadone and drug-related 
deaths is not straightforward. Detoxification increases the risk of drug-
related harm from loss of tolerance and overdose.2
This does not mean detoxification is a bad thing, it means that it has to be done 
at the right time, with the right people and in the right way. So Tim Leighton 
argued at Edinburgh that there is no evidence of a link between “properly 
supported abstinence” and higher rates of mortality. He continued that “crass 
abstinence-based treatment can really traumatise people … and I’ve been 
working within the system to try and minimise that. Men and women are at risk 
of being dumped into something for which they have not been prepared and 
which can have a harmful effect on them.”3
Another contributor to the debate at Edinburgh argued that the risks of drug-
related deaths and health problems had to be understood in the wider context 
of people’s lives – with many clients having multiple needs and problems (for 
example, homelessness or lack of access to primary care services). She said that 
“people who die of drug-related deaths have multiple complex issues” and that 
“methadone – and their drug use – are only a small part of the overall issues 
that are affecting them.” She complained that “often it is about services not 
communicating with each other to identify those people that are at highest 
risk … When you turn up to drug-related death meetings everybody has got 
copious amounts of information on the person who has died, but very few of 
the services have actually been talking to each other.”
1 probation circular pc23 (2007), Reducing the risk of drug-related deaths, p. 2 (www.probation.
homeoffice.gov.uk/files/pdf/pc23%202007.pdf)
2 see, for example, the nta guidance Reducing Drug-Related Deaths (2004), which explains that 
‘recent evidence suggests that detoxification may carry a significant overdose risk for those 
who are “successful” (in initially achieving abstinence)’. in particular, it cites, Loss of tolerance 
and overdose mortality after inpatient opiate detoxification: follow-up study. John strang, 
Jim mccambridge, David best, tracy beswick, Jenny bearn, sian rees, michael gossop. British 
Medical Journal, may 2003; 326. the evidence on links between detoxification and drug-
related harm (including drug-related deaths) are also examined in mike ashton’s ‘the new 
abstentionists’. 
3 in manchester, paolo pertica argued that we need to take a longer term view of the relationship 
between treatment modalities and risks of drug-related deaths. “how many of those on 
methadone maintenance are using other drugs as well?” he asked. “What will the long term 
effects of methadone maintenance be on the liver?” (he also questioned whether it was 
appropriate to compare people who had dropped out of abstinence-based programmes with 
people who were still in maintenance programmes.) a debate participant who was involved in 
research into drug-related deaths, argued that “not very many people die of methadone… of 
those who do, the point has already been made that much of it is illicit.” 
Drug treatment at the crossroaDs
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“someone said that detoxification kills. as is often the case when 
we have a headline like that – and that is a headline – he then 
went on to say this applies if it is supplied by cowboys, who don’t 
know what they are doing, to the wrong people.”
Brian Kidd, Deputy Chair, Scottish Association of Alcohol and Drug Action 
Teams, Chair, The Great Debate, Edinburgh 
MESSAGE 2 There is broad agreement that abstinence is marginalised within drug 
treatment provision. For example, one floor participant in Manchester who 
described himself as a ‘hard core harm reductionist’, was nonetheless concerned 
that “when people say they want to stop using, they’re told that ‘you are not 
ready yet’”, adding “I’ve worked in the field for twenty years and I don’t think it 
is my decision to say to someone ‘you are not ready.’“
Richard Phillips, speaking at the London (Birkbeck) Great Debate, felt that 
“there appeared to be a crisis within the residential rehab sector … this form 
of treatment has been severely marginalised in the overall drug treatment 
system to the point that it has been in decline for the last few years […]. In this 
country”, he concluded, “it has been the abstinence-based services that have 
been in decline and outside of the policy and planning loops.”
“you can have a system that can support those who are not 
willing or able to get ‘clean’ – and you can help them with 
interventions such as methadone prescribing – but at the same 
time we should be able to help and support those who wish to 
become drug-free. aside from anything else, this is about client 
choice. yes, by all means, there are clients who wish to be on 
methadone, but there are also others who do not want to be, and 
there should be services for them too.”
Paolo Pertica, Head of Blackpool Community Safety and Drug Partnership, 
The Great Debate, Manchester 
MESSAGE 3 Service users must be involved in decisions about their own treatment. 
The fact that many service users say they would ideally like to become drug-free 
does not mean they are ready for abstinence. Conversely, service users have the 
right to have their own informed decisions about treatment taken seriously by 
service providers. In other areas of medicine, patients may opt for treatments 
that have some risks attached because they believe these are outweighed by the 
potential benefits.
“i think we have become very risk averse in substance misuse. 
We have got to a point, because people say detoxification kills, 
where we are not prepared to let people try and come off drugs 
because we are terrified that they are going to die… but … the 
being sensible about abstinence
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challenge is about detoxifying people in the right circumstances, 
… involving people in decisions about their care, and setting the 
risks before them. if you had cancer, a doctor would sit down with 
you and lay out the options for you, … treating you like a human 
being and allowing you to make choices about that.”
Brian Kidd, Scottish Association of Alcohol and Drug Action Teams, Chair, The 
Great Debate, Edinburgh 
“i started asking ‘What is your service about? What do you mean 
by treatment? how can my son access this treatment? how do you 
evidence this treatment? […] What is the success for outcomes 
of people moving on from methadone?’ the thing that shocked 
me most is that people closed ranks on me. i would say, if there 
is anything to learn from today, it is that people do need to 
have evidence of outcomes. We do need solid research. We also 
need to listen to what service users are saying. it is about having 
meaning and connection in their lives, it is about understanding 
how they are going to be able to move forward.”
Carer, speaking from the floor, The Great Debate, Edinburgh.
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Drug treatment services should support both harm 
reduction and abstinence-based approaches. There are 
many routes into drug dependency and many journeys 
out of it. 
Beyond abstinence versus 
harm reduction
“I have to confess, I have no little trouble fathoming how 
on earth we have ended up here, once again engaged in the 
obsessive navel-gazing that is the debate about whether the 
focus of treatment should be abstinence or maintenance?
“It’s just not a question that I can identify with, because people 
experiencing drug treatment need the opportunity to choose 
the interventions that work best for them. This might change 
through someone’s drug using career, with needle exchange, 
drop in, prescribing, inpatient and community detox and 
residential or community rehabilitation services coming into 
play at different points for different people. Sometimes, as we 
know, people will not move through these interventions in any 
convenient linear mappable way, but may well drift in and out of 
treatment over a protracted period of time.
“So is the aim abstinence? Yes. Is it maintenance? Yes. Do we 
need harm reduction? Yes. Is prevention important? Yes.
“There is no right or wrong answer and really there should be 
no debate about this. There is no “one size fits all” solution to 
the problems people who use drugs face. I have as little time for 
people who say everyone needs a script as I do for those who say 
everyone needs to go to a fellowship group.”
Sara McGrail, The Great Debate, London (Birkbeck)
There were differences of opinion at The Great Debate meetings on the best 
balance between abstinence and harm reduction approaches, but nobody at 
any of the sessions argued (at least explicitly) for either extreme abstinence 
(and the exclusion of harm reduction services) or extreme harm reduction (and 
the exclusion of abstinence-based services). The need for both types of service 
is a matter of broad consensus, it is the appropriate balance and relationships 
between them that is at issue.
2.3
“We should be moving 
people who have been 
on methadone, who 
have attained the 
much wanted stability 
… into a drug-free 
environment where 
possible, because 
that gives them the 
opportunity for full 
recovery, not just 
stabilised ongoing drug 
use.”
Professor Neil McKeganey, 
Centre for Drug Misuse 
Research, University of 
Glasgow, The Great Debate, 
Edinburgh
beyonD abstinence versus harm reDuction
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“… within the political sphere, i think there is reason to be 
anxious. […] there is a real question about how the field positions 
itself in this debate and within the political argument to make 
sure that we don’t allow the politics to pose a threat to continued 
investment in harm reduction. but we need to be clear that 
abstinence-oriented services are at risk too. there has been a 
real terms reduction in overall numbers of people going into 
residential rehab over at least a two year period and a reduction 
in the overall number of beds within the sector. it is very difficult 
to reopen these facilities once they’ve been closed … i believe we 
all need to defend the existence of abstinence-based provision 
within a system with an overall focus on harm reduction.”
Richard Phillips, Independent Consultant – Substance Misuse, The Great 
Debate, London (Birkbeck)
Key messages taking us beyond abstinence  
versus harm reduction
MESSAGE 1 There are a variety of routes into drug dependency and a variety of 
journeys out of it. Recovery journeys are various, complex and require 
different forms of support and engagement at different points, in what can be a 
long process. We need a range of evidence-based services that provide the right 
kind of help in the right way at the right time.
MESSAGE 2 Care pathways out of dependency must be individualised, which means 
service users themselves must be at the centre of the process. If a range 
of services is available, how do we decide which service is best for a particular 
individual at a specific time? This requires a combination of needs assessment 
(for example, through care planning) and a responsiveness to informing and 
supporting service users to make their own decisions.
A GP working with drug users commented at The Great Debate in London 
(Birkbeck) that neither abstinence nor harm reduction were ‘best’ in any 
abstract or generalisable way. This was because “people’s recovery needs to 
be individualised and tailored to the approach most suitable to their needs,” 
working from a position of “What is right for them?”.
“treatment services can be incredibly egotistical about their role 
and their importance in someone’s recovery … We get bogged 
down in a debate about harm reduction or abstinence that 
probably does not mean a huge amount to a lot of service users. 
We should be focussing on the individual service user’s perspective 
and how they define their pathway to recovery.”
Speaker from the floor, The Great Debate, Manchester
Drug treatment at the crossroaDs
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MESSAGE 3 The way services are delivered and the way they relate to service 
users is important. As in other fields, such as mental health, the values, 
competencies and attitudes of staff working in drug services is as important as 
the particular intervention they are delivering and possibly more so.
“people can change, their lives can be turned around, but 
by special people who stick with their clients and can instil 
optimism and hope, and whose relationships often go well 
beyond treatment to include more subtle things – intensive case 
management, supported housing, support into employment, etc.”
Paolo Pertica, Head of Blackpool Community Safety and Drug Partnership, 
The Great Debate, Manchester 
MESSAGE 4 The relationship between harm reduction and abstinence-based services 
is important. Services are too inclined to work in silos, failing to facilitate 
the kind of recovery journeys that make best use of the full range of available 
services given the particular needs and choices of service users.
“What we should be doing is drawing abstinence-based and harm 
reduction services closer together and understanding what the 
relationship between them should be.”
Richard Phillips, Independent Consultant – Substance Misuse, The Great 
Debate, London (Birkbeck)
29
People with serious drug problems are often 
stigmatised, socially excluded and marginalised. It is 
important to recognise the formidable barriers that 
stand between them and a decent quality of life.
Social (re)integration – 
making a reality of recovery
 “When people start getting into that hole of addiction, we push 
them further down and then we haul up the ladder so they 
can’t get out … We systematically dismantle all the things they 
could haul themselves out with. Their homes are gone, they are 
criminalised, they are stigmatised, they lose touch with their 
families. No one wants to know them, no one wants to house 
them,[…] they have no hope of a job. This is something that 
society does to them. It makes it impossible for them to recover 
and then society says ‘ah you have got a chronic relapsing 
condition, haven’t you?’ … Of course they relapse when we treat 
them in this way.”
Mike Ashton, Editor, Drug and Alcohol Findings, The Great Debate, Edinburgh 
Many people in the drug treatment system have multiple needs and damaged 
lives. People will struggle to tackle a drug problem successfully if they face 
stigma and marginalisation, homelessness and/or have no access to training, 
employment, or other meaningful activity.
Care pathways out of addiction are about a lot more than drug treatment  
per se.
A valid objection to a system that is over-reliant on ‘parking’ people on 
methadone is that it has done too little to support service users to access social 
capital and move on with their lives.
A valid objection to simplistic variants of New Abstentionism is that it is not 
realistic to expect people to become drug-free, so long as problems from their 
past are unaddressed (such as experience of trauma and abuse), problems in 
their present persist (such as homelessness), and they see little prospect of a 
better future for themselves (for example, of meaningful employment or of 
reconnecting with families).
2.4
“What is needed, 
ultimately, is decent 
social policy to 
meliorate the dire social 
conditions, endemic 
poverty and decrepit 
housing and education 
systems which leave 
so many of the under-
privileged seeking 
solace and escape from 
their social world.”
Dr Eliot Ross Albert, 
Director of UK Harm 
Reduction Alliance and 
founder member of London 
User Forum, The Great 
Debate, London (Birkbeck)
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“to focus on whether somebody is using drugs is to miss the point 
… What matters is the quality of their lives and their contribution 
to society.”
Dr Eliot Ross Albert, Director of the UK Harm Reduction Alliance and founder 
member of the London User Forum, The Great Debate, London (Birkbeck)
“part of the reason i think we get into such confusion over this is 
we are using the wrong language, the wrong models – the wrong 
everything – for the wrong debate. We are talking about ‘harm 
reduction’ … about ‘treatment’ … about ‘abstinence’, but these 
are all medical ideas. Drug use is a poverty issue … it is largely an 
issue of deprivation … When we have a child with asthma we give 
them an inhaler. We don’t go around to their house and get rid of 
their damp.
“We are all on little islands trying to deal with individuals living 
in absolute poverty – not just poverty of money, but poverty of 
aspiration and education. that is a huge job and it is why people 
relapse. When we use language like abstinence, treatment and 
recovery, we are using medical language for what is a social care 
issue.”
Speaker from the floor, The Great Debate, Edinburgh
Key messages on recovery and (re)integration
MESSAGE 1 Recovery does not have to mean abstinence. If people only have access to 
things like housing and meaningful activity after they have become drug-free, 
then they get access to the social capital they need to beat dependency only 
after it has already been beaten. It is a Catch 22.
“Focusing on abstinence as a requirement for other services, 
such as housing, denies people whose short term goals will never 
include abstinence the opportunity and support to further move 
on in their recovery. in particular, we feel that moving people 
away from inadequate housing would help to move drug users on 
to becoming drug-free in the long term.”
Jason Wallace, Service User and Volunteer, Scottish Drugs Forum, The Great 
Debate, Edinburgh 
MESSAGE 2 For many service users, recovery is a long and winding road – not one 
bound and you’re free. The NTA’s Models of care for treatment of adult 
drug misusers: Update 2006 states that “drug treatment is not an event, but 
a process usually involving engagement with different drug treatment services, 
“What services need 
to realise is that they 
[should] be answering 
the question ‘is their 
service contributing 
to a client believing 
that life is better in 
treatment than it was 
when they were using 
drugs?’“
Speaker from the floor, 
The Great Debate, London 
(Birkbeck)
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perhaps over many years.” The NTA cites evidence from the United States which 
concludes that an average time in treatment for problem drug users is five to 
seven years. Few problem drug users who enter treatment will be ready to leave 
the system in a few weeks or months.
“the situation is very similar for ex-homeless clients: you can’t 
remove the substance use without all the other services being 
in place. harm reduction or abstinence doesn’t matter, it comes 
down to the need to improve an individual’s quality of life over 
all else. this means recognising the complexity of people’s lives 
and support needs and that, for some people, success will not be 
measurable in a twelve week period. it may take two to three 
years to see improvements and individual treatment successes.”
Speaker from the floor, The Great Debate, London (Birkbeck) 
MESSAGE 3 The barriers that prevent problem drug users from accessing things like 
housing and employment are serious and entrenched. Where are housing 
and employment for people with serious long-term drug problems going to 
come from? What about the stigma and discrimination that confronts people in 
drug treatment as they work to (re)build their lives? What about people whose 
needs are so complex and acute that they will not be ready to (re)enter the 
mainstream economy for the foreseeable future?
“i think there is a consensus now about services moving away 
from medicalised treatment to these new social approaches, but 
there is not yet really a recognition that they are going to have 
to be very intensive and resource heavy if they are going to work, 
because you are addressing the needs of people with multiple and 
complex problems.”
Speaker from the floor, The Great Debate, Edinburgh 
MESSAGE 4 Employment is important – but it is very difficult for many people in 
drug treatment to get into education, training or work. In Edinburgh, 
a service user volunteer with the Scottish Drugs Forum made clear that work 
was a priority for many drug service users. Areas that service users wanted 
more help with included “housing and council tax arrears, money and finance 
advice and information, access to volunteer work, access to education and 
training.” Specifically, he said that “a big barrier in moving into education and 
employment is having to collect a daily script and the stigma attached to just 
being on one rather than the ability to actually move on.”
“in terms of recovery it is absolutely crucial to get drug users – 
recovered drug users – into employment because employment 
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opens up a whole range of opportunities to build a non-addict 
identity, to form relationships with people who are not involved 
in drug use.”
Professor Neil McKeganey, Centre for Drug Misuse Research, University of 
Glasgow, The Great Debate, Edinburgh 
MESSAGE 5 Many drug users have highly damaged lives, difficult personal histories 
and complex needs – recovery is about much more than drug treatment. 
Many of the people who use drug services arrive at the door with problems 
that are like big and complicated knots that have to be carefully unpicked. For 
instance, drug service users may be homeless or have mental health problems; 
they might have been abused as a child or worked in the sex trade.
“When we’re talking about recovery, we should be asking how do 
you recover if you’re a woman and you’ve been abused by your 
father, you’ve been put in a paedophile ring, and heroin takes you 
away from that, it helps you not to think about that?”
Speaker from the floor, The Great Debate, Manchester 
MESSAGE 6 If we are going to do recovery, we need to be doing it properly. Realising 
the positive potential of the recovery or (re)integration agenda requires serious 
investment and fundamental changes to the way many services operate. A 
widespread fear is that these concepts will serve a primarily ideological role in 
the development of public debate and public policy – with the focus on the 
responsibilities of service users and the role of drug services, and not upon the 
wider causes, contexts and consequences of problem drug use.
“Whatever happens, it is a fair prediction that we’re going to see 
a lot more managers with recovery in their title and a lot more 
recovery champions – whatever the flavour of the month or year, 
it tends to get reflected in the job titles that people are given, 
without necessarily having much impact on anything that actually 
gets done.”
GP from the floor, The Great Debate, Manchester
“if we believe in recovery as anything more than a rebadging … 
then we have to be much clearer about how important it is to 
help people turn their lives around and that a decision to engage 
in that enterprise is actually fundamental to the lives of citizens in 
this country who find themselves in trouble with drugs.”
Ian Wardle, Chief Executive, Lifeline, The Great Debate, Manchester
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3
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“I am concerned about […] the perception 
of this as a very polarised debate. There 
is the idea that a chasm is opening up 
between those who believe in abstinence 
and those who believe in harm reduction. 
But if this is allowed to become a binary 
debate it is going to be very damaging for 
us as a field. It will make us much less able 
to defend what has been achieved over 
the last few years in both harm reduction 
and abstinence.”
Richard Phillips, Independent Consultant – Substance Misuse, The 
Great Debate, London (Birkbeck)
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Next steps
It would be misleading to pretend that there were not significant disagreements 
at The Great Debate sessions. Key areas of debate included:
l	the value of methadone maintenance;
l	the nature of the relationship between abstinence-based approaches and drug-
related deaths;
l the appropriate balance between abstinence and harm reduction services; and
l the relationship between abstinence (or progress towards a ‘drug-free’ life) and 
recovery (including access to specific forms of social capital such as housing and 
employment).
At the same time, there is a wide area of consensus and the contours of a 
reinvigorated and enriched drug policy paradigm were discernible at The Great 
Debate meetings. In particular, there was unanimous support for continued 
government investment in drug treatment, with some of the biggest critics of 
current policy – coming from both harm reduction and abstinence perspectives 
– arguing for greater investment, not less.
There was also general agreement that:
l	the drug treatment sector should provide a range of services, including 
both harm reduction and abstinence-based approaches.
l	there are various routes into drug dependency and many routes out of 
it – typically, service users will need different kinds of intervention at different 
points in their recovery journeys.
l	most people seeking help with drug problems have other problems, 
which are the causes, contexts and consequences of their drug problems – 
these can include a history of trauma and abuse, mental health issues, housing 
problems, lack of skills, unemployment, poverty and experience of stigma.
l	we need to develop a more social model of recovery, which is about 
repairing damaged lives and giving people things to live for, not simply treating 
addiction.
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l	this requires a sophisticated approach to care planning, that recognises 
that linear care pathways will often not be effective for people with 
multiple needs. It is not realistic to expect people to come off drugs before 
they access basic social capital such as housing and employment.
l	this is about services that are much more responsive to the specific 
problems and motivations of particular service users at definite points 
in their recovery journeys; it is about more individualised and personalised 
models of care.
There are real opportunities at present, and solid commitments in both the 
Scottish and English drug strategies that hold out the prospect of further 
progress. At the same time, there is concern that the opportunities to move 
things forward presented by the current focus on recovery and social (re)
integration could be lost.
They could be lost if respect for clinical judgement and evidence-based service 
provision is over-ridden by a dogmatic and ideological approach, that pitches 
abstinence against harm reduction. They could be lost if politicians come to 
see drug treatment service users as an easy target for populist and stigmatising 
rhetoric and policies. Delivering social inclusion for such a marginalised, 
excluded and stigmatised section of the community is going to require 
significant investment – so where is the money to come from? Or, perhaps 
more realistically, how are existing resources going to be used, and access to 
them improved, to accommodate this new source of demand – for example, in 
housing, in education or employment?
If we are willing to make the investment and develop robust, evidence-based 
policy, the gains to drug service users, families, neighbourhoods, communities 
and society as a whole are potentially huge.
This brings us to the final challenge – to argue for investment in drug treatment 
on the basis of compassion and not simply fear. Yes, some problem drug users 
commit crimes to finance their dependency. Yes, some problem drug users on 
welfare benefits make little effort to find employment. These are legitimate 
political concerns. But we are talking about a group of people who often have 
highly damaged lives. We are talking about a group of people who can find 
it incredibly difficult to get into housing, education, training or work – who 
experience high levels of social stigma, marginalisation and exclusion. We are 
talking about broken families, severed community ties, stigma, marginalisation 
and often chronic exclusion.
This task may seem daunting, but we have plenty of good work to build on. 
We have made huge strides forward in improving access to drug treatment in 
Britain, and this has delivered real and substantial benefits for the community. 
Paolo Pertica, Head of Blackpool Community Safety and Drug Partnership, 
quoted the Joni Mitchell lyric ‘you don’t know what you’ve got ’til it’s gone’ to 
make the point that, for all the concerns, there is a lot to celebrate in the drug 
treatment sector. It is about how we move forward from here.
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Recommendations
reshaping the Debate
1 Politicians from all parties should publicly commit to an evidence-based 
approach to drug policy. The advice of independent experts, such as the 
ACMD and NICE, must be respected. Only evidence based treatment will deliver 
positive outcomes for drug users, families and carers, neighbourhoods and 
communities. In this respect, the same principles apply to drug treatment as to 
the treatment of cancer, heart disease, diabetes, depression or schizophrenia. 
Where investment in drug services is driven by research and evidence, it delivers 
for taxpayers and is cost effective too. 
2 The Government should fund, develop and implement a 
communications strategy to inform the public about the achievements 
of front-line drug services. If government is to continue to deliver the 
substantial public benefits achieved through investment in drug treatment, it 
needs to ensure public support for treatment services. The Home Office and 
the NTA must support local partnerships to develop communications strategies 
that engage with their local communities, local government, local media and 
local politicians. Furthermore, there is an urgent need to address negative 
attitudes and discrimination against people who are in or who have been in 
drug treatment. Work should be undertaken – for example, by the EHRC and 
the NTA – to address this, perhaps through the creation of a campaign similar 
to the SHiFT campaign for mental health. Negative perceptions of people who 
are in, or who have been in, drug treatment remain a major barrier to social 
(re)integration and yet the government has made no public commitment to 
addressing this. The EHRC could take a lead in mapping and addressing the 
attitudinal barriers that work against people with a history of substance misuse 
as they try to get their lives on track. 
rights anD choices
3 Drug treatment services must address diversity issues more effectively. 
The EHRC and the NTA should work together to improve the responsiveness 
of drug treatment services to race, ethnicity, culture, religion, gender, sexuality, 
3.2
The following recommendations were not discussed 
at The Great Debate meetings, but emerged from 
DrugScope’s subsequent reflections on the debate.
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age and disability. Recent debate about abstinence and substitute prescribing 
has pushed other important issues to the margins of the public debate about 
drugs and drug treatment. It is striking, for example, how little consideration 
has been given to cultural differences in perceptions of the respective roles of 
abstinence and maintenance prescribing. Again, there is a role for the EHRC 
and an opportunity for the NTA to give a higher profile to these issues with the 
introduction of new single equalities legislation.
4 Drug treatment should be provided in accordance with the new NHS 
Constitution. This means that every service user entering drug treatment 
should be provided with a statement of their rights and responsibilities as well 
as clear and unbiased information about available treatment alternatives. Service 
users are entitled to make decisions about treatment. This should include a right 
to choose a treatment approach that potentially delivers a preferred outcome 
(for example, abstinence), but at a higher risk of failure than some alternatives. 
But respect for choice is fundamental within health services. It can contribute to 
positive treatment outcomes by building therapeutic relationships and boosting 
motivation and self-esteem.
5 Drug service users should be involved in decisions about their 
treatment. Every drug user entering the treatment system should have an 
effective and comprehensive care plan which should be regularly reviewed with 
a designated key worker. Their needs should drive the care planning process, 
and they should be fully involved in it. This should include plans for people 
on substitute drugs to move off them, when they are ready and appropriate 
support is in place. People with drug problems often have complex needs. 
They need individualised pathways out of dependency alongside support from 
a variety of agencies. An NTA review found that care planning was ‘good’ or 
‘excellent’ in only 26 per cent of local partnerships. This must be addressed. A 
good starting point would be more detailed research on current provision of 
care planning. This would also ensure that people are not indefinitely ‘parked’ 
on methadone and services are pro-active in facilitating social (re)integration. 
6 There should be further research on alternatives to substitute 
prescribing. Psycho-therapeutic, psycho-social and abstinence-based 
approaches should all be investigated, by a body such as NICE, along with 
options for the treatment of a wider range of drug problems. There is broad 
consensus in the drugs field that the treatment system is over-dependent on 
substitute prescribing. No substitute drugs are available to help with many of 
the most damaging forms of substance misuse. We need investment from the 
government into research on alternatives to substitute prescribing but also 
into how the provision of ‘social’ support (for example, housing) contributes 
to successful drug treatment outcomes. We need to back up the findings of 
research with investment in evidence-based practice.
7 There should be further work to reduce drug-related deaths. Abstinence-
based services (including services in prisons) should be required to have robust 
policies for managing relapse and the associated risks, particularly overdose. 
There is a significant increase in risk of overdose following detoxification or after 
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a period of abstinence (for example, in prison). This does not mean that people 
should not be detoxed when they are ready, but it does mean that abstinence-
based services need to have clear protocols for managing risk (including referral 
routes to harm reduction services). 
Working together to improve outcomes
8  All local drug partnerships need to develop effective partnerships with 
other local agencies. These would include JobCentre Plus, housing providers 
and mental health services. For example, it is often the case that drug treatment 
service users need somewhere to live before they can make progress with drug 
problems. But many housing associations and domestic violence refuges will 
not accommodate people who are not abstinent. Evidence from participants in 
The Great Debate suggests that relationships between services are much better 
developed in some areas than others. As long as drug treatment works in a 
silo, we will fail to deliver on key recovery and social re-integration objectives. 
It may be necessary to create new roles or redesign existing ones to provide 
a better structure for developing and maintaining relationships between key 
stakeholders and agencies (an example could be the creation of drug co-
ordinators within JobCentre Plus).
9 There should be clear recognition of the contribution of families, carers 
and other support networks to recovery. Better support should be available 
to them (including appropriate financial support). Families and other informal 
networks play a huge role in supporting recovery and providing recovery capital 
– such as housing. We need further research to identify the benefits provided 
by these networks, and the support that is available to them. They need to be 
helped to move in from the margins of the drug policy debate. 
10 The next round of the Comprehensive Spending Review should 
introduce treatment outcome targets that include re-integration. For 
example, we should be increasing the numbers of drug users moving into 
quality housing or education, training and employment, as a key policy priority. 
The Public Service Agreement on reducing the harms caused by drugs and 
alcohol (PSA 25) includes two crime reduction measures, but no indicator of 
treatment outcomes other than reduced offending, and no indicator of social 
(re)integration. Elsewhere, the Public Service Agreement on chronic adult social 
exclusion (PSA 16) does not identify people with drug dependency problems 
as a key target group. This should be addressed in the next round of the 
Comprehensive Spending Review.
During The Great Debate sessions, there was also general agreement that to 
move forward, we need to widen the debate to look at emerging patterns of 
drug use and different forms of intervention. It was felt that the NTA should 
lead on the development of a drug treatment system that can improve the lives 
of people with a wider range of substance misuse problems, including polydrug 
and alcohol misuse. 
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Recent debate about drug treatment has really been about heroin treatment. 
There are no viable substitute drugs for stimulant use, nor do we have a 
coherent regime for polydrug problems. But if we persist with a narrow 
definition of problem drug use we are unlikely to be well equipped to meet 
new challenges as drug trends change. Those young people gearing up to be 
the next generation of ‘problem drug users’ appear to be developing problems 
linked to cheap alcohol and cocaine, maybe along with cannabis, ecstasy and 
tranquillisers. The question is, to what extent are drug services equipped for 
this and how flexible can they be? We also need to think seriously about a joint 
drug and alcohol strategy.
Participants at The Great Debate almost all agreed that prevention was an 
issue that needed both more research and more investment. There was broad 
consensus with the idea that the Government should fund research to identify 
ways that we can get upstream and reduce both problematic drug use and 
the demand for drug treatment. A framing assumption for current debate 
is that there will be an endless supply of new entrants into the system but 
the problems that these new entrants bring might not resemble those of 
their predecessors. At present, drug treatment provision is almost exclusively 
fixated on ‘acute’ and ‘crisis’ services. In the future, we might seek to balance 
‘low visibility, acute need’ treatment service provision with higher visibility, 
community services, that are accessible to people who may be beginning to 
develop drug problems or have concerns about others. To this end, we should 
also be working to improve the engagement of primary care services with the 
delivery of drug treatment interventions.
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Last words …
“Actually we’ve found that there is much more common ground 
than there are disparate views. Often, the same issues are raised 
[...]. It is not about whether abstinence or replacement prescribing 
was available. It is about whether what the person needed at that 
time … was available at the right time and whether that support 
was flexible enough to move with that person as they moved.”
Brian Kidd, Scottish Association of Alcohol and Drug Action Teams, Chair,  
The Great Debate, Edinburgh
“We want a more detailed and sensitive discussion that is 
informed by evidence, but also by values of care and compassion.”
Professor Susanne McGregor, London School of Hygiene and Tropical 
Medicine, Chair, The Great Debate, Manchester
“I think we do know what treatment is. I think anyone who’s 
been involved in effective treatment – as a punter or as a 
worker – knows exactly what it is. It’s a good relationship, a 
proper dialogue between client and worker, the trust, time and 
opportunity to access whatever it is our clients need to keep them 
safe, keep them alive and help them choose to move on. Whether 
that’s abstinence or maintenance.
“It’s probably time we stopped getting so screwed up about 
our traditional rivalries. We need to defend what we do, not by 
looking inwards at debates like this, but by opening an honest 
dialogue with the rest of society and beginning to say out loud 
the things we all know. People are different. Good drug treatment 
responds to that difference, offers choices, is not rigid or 
doctrinaire but works flexibly with the individual. That’s how drug 
treatment changes people’s lives. And that’s what we do.”
Sara McGrail, Freelance Drug Policy Specialist, The Great Debate,  
London (Birkbeck)
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Key facts and figures on 
drug treatment
The wealth of data available on drug treatment, particularly since the 
establishment of the National Drug Treatment Monitoring System1 (NDTMS) in 
2001, is invaluable, but it can be overwhelming. The next few pages detail some 
key facts and figures surrounding drug treatment in England in order to provide 
an accessible guide to the subject and place The Great Debate in context.
The majority of data has been sourced from the annual ‘Statistics from the 
NDTMS’ reports, published by the NTA since 2003/042. References are provided 
where other sources have been consulted.
1 national Drug treatment monitoring system (http://www.ndtms.net/)
2 the full reports can be downloaded from the nta ‘Drug treatment activity’ web page:  
http://www.nta.nhs.uk/areas/facts_and_figures/national_statistics.aspx
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Background: the structure of drug treatment  
in England
If someone needs help with a drug problem, there are various routes into 
treatment available. Users can access these services via a GP referral or drugs 
advice service or through the criminal justice system.
In England, the NTA introduced the Models of Care framework in 2002 
(updated in 2006). This framework provides four tiers of different drug 
treatment services, classified in a way that is easy to understand. The framework 
should, in theory, mean that individuals can choose from a range of services 
available to them and move through the tiers according to their needs.
A breakdown of the types of intervention and treatment providers available in 
each tier of treatment is as follows:
Tier Type Examples of interventions Examples of providers:
1 non-specific (general) info and advice •
screening for drug misuse •
referral to specialist services •
general practitioners •
probation services •
housing providers •
helplines •
2 open access info and advice •
harm reduction interventions  •
referral to structured drug  •
treatment
brief psychosocial  •
interventions
specialist drug services •
drop-in clinics •
pharmacies •
3 community services substitute prescribing •
structured day care •
counselling and therapy •
community detox •
harm reduction as part of a  •
care plan
community drug teams •
some gps offer substitute  •
prescribing  
4a specialist residential 
services (residential)
inpatient treatment •
residential rehabilitation •
opiate detox •
residential drug services •
hospitals •
4b highly specialist (non-
substance misuse)
liver units •
forensic services •
hospitals •
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Individuals in contact with drug treatment
The last decade has seen a substantial rise in the number of individuals in 
contact with drug treatment services. In 1998/99 there were 85,000 clients 
engaged with treatment providers but ten years later this level had risen to 
almost 203,000, representing an increase of around 238%.
Number of individuals in contact with drug treatment services  
between 1998/99 and 2007/08 
Figure 1: Number of individuals in contact with drug treatment services  
1998/99 to 2007/08 
Year 98/99 99/00 00/01 01/02 02/03 03/04 04/05 05/06 06/07 07/08
no. of 
individuals in 
contact with 
treatment
85,000 91,000 99,000 116,000 115,500 125,545 160,453 177,055 195,464 202,666
Investment in drug treatment
Recent years have seen an increased investment in drug treatment services. 
Funding is predominantly provided by government via the Pooled Treatment 
Budget (PTB) and local-level funding.
The PTB is combined funding from the Home Office and the Department of 
Health, allocated annually to local Drug Action Teams (DATs). Up until and 
including 2007/08, the amount allocated to each DAT was based on a formula 
which calculated local need utilising key deprivation factors. However, concerns 
over the wide variation in PTB allocation per head, led to a revised formula 
being introduced in 2008/09. 
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As part of the NTA’s attempt to ‘introduce a fairer criterion for allocating 
funding’, the new formula takes into account factors such as the caseload 
complexity of local treatment populations, the mix of cases of problem and 
other drug users, and area cost differentials that exist. 
PTB funding rose from £142 million in 2001/02 to £396 million in 2007/08. 
In a letter announcing the record £396 million 2007/08 PTB in January 2007, 
NTA Chief Executive Paul Hayes said it was ‘unlikely’ that there would be 
further increases in PTB funding during the period 2008-11 and consequently 
“...continued expansion and improvement of the system will therefore be 
dependent on growth in local funding, and in particular on more effective use 
of existing resources.”3 It was therefore welcome news when the 2009/10 
budget was announced (February 2009) – it will stand at £406 million. It is 
important to note, however, that while funds have been increasing, the number 
of clients in treatment has also risen year on year. In real terms, the amount of 
money available to spend per client has actually been decreasing.
At local level, DATs also receive funding from organisations such as Primary Care 
Trusts, local authorities and probation services who work with client groups 
affected by substance misuse. During the period 2001/02 to 2006/07 local 
funding allocations rose from £145 million to £212 million. At time of writing 
figures for ‘local funding’ and ‘total investment’ were only available up to 
2006/07 on the NTA website.4
DATs use this combination of central government and local funding to 
commission drug treatment services from NHS, voluntary sector and sometimes 
private sector providers, to meet their local needs.
Total investment in drug treatment services 2001/02 to 2006/07
3 http://www.nta.nhs.uk/about/funding/docs/nta_ptb_announcement_phletter_290107.pdf
4 http://www.nta.nhs.uk/about/funding/drug_treatment_services.aspx
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Figure 2: Investment in drug treatment services 2001/02 to 2006/07
Expenditure on drug 
treatment (excluding  
prison-based treatment) 
2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08
pooled treatment budget £142m £191m £236m £253m £300m £385m £396m
local funding £145m £131m £200m £204m £208m £212m n/a*
total investment £287m £322m £436m £457m £508m £597m n/a*
*As mentioned above, at time of writing figures for ‘local funding’ and ‘total investment’ were 
only available up to 2006/07 on the NTA website.
Some treatment services run by voluntary sector providers may gain additional 
funds through fundraising as charities. There are also several private sector 
providers, particularly of residential rehab services. Normally people who attend 
these clinics pay for the treatment themselves although sometimes DATs may 
buy places in these services where necessary.
Number of problematic drug users in treatment
According to the NDTMS there were 150,075 problematic users engaged in 
drug treatment in 2007/085. The most reliable gauge of problem drug use 
estimated that there were around 328,767 opiate and/or crack cocaine users in 
England in 2006/07.
The majority of individuals (123,522) in contact with treatment in 2007/08 cited 
heroin as their primary drug of use. The next most common primary drug cited 
was cannabis (26,287).
Primary drug of misuse of individuals in contact with treatment 2007/2008 
5 home office (november 2008), National and regional estimates of opiate use and/or crack 
cocaine use 2006/07: a summary of key findings 
Ecstasy 1%
Other drugs 3%
Amphetamines 3%
Other opiates 3%
Crack 5%
Methadone 5%
Cocaine 6%
Cannabis 13%
Heroin 61%
Figure 3: Primary dr g f misuse of individuals in treatment 07/08
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Figure 3: Primary drug of misuse of individuals in treatment 2007/2008 
Primary drug of use Percentage Number
heroin 61% 123,522
cannabis 13% 26,287
cocaine 6% 12,613
methadone 5% 10,112
crack 5% 10,994
other opiates 3% 5,447
amphetamines 3% 5,703
other drugs 3% 6,170
ecstasy 1% 1,059
total 100% 201,907
Clients retained in treatment for twelve weeks
Research-evidence indicates that drug treatment is more likely to be effective 
if clients are retained in treatment for 12 weeks or more6. Retention for this 
period (or longer) can lead to significantly improved treatment outcomes 
including reductions in drug use, drug-related crime and drug-related deaths. 
Since 2005/06, the NDTMS has collected data on the number of clients who 
entered treatment each year whose treatment journey lasted longer than 12 
weeks. Beginning in 2006/07 national targets have been set for retention, 
although these have yet to be met.
Figure 4: Clients beginning a treatment journey who were retained in treatment  
over 12 weeks
Individuals being retained 
for over 12 weeks
2005/06 2006/07 2007/08
no of clients beginning 
treatment 
83,030 80,280 82,381
no who were retained in 
treatment for over 12 weeks
62,972 60,392 64,440
percentage retained for over 
12 weeks
76% 75% 78%
national target for retention  n/a 77% 83%
6 nta (2005) retaining clients in treatment: a guide for providers and commissioners  
http://www.nta.nhs.uk/publications/documents/nta_retaining_clients_in_drug_treatment_2005.
pdf
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Individuals discharged from treatment drug-free
The NTA publish statistics on individuals ‘discharged from treatment’. Clients 
who are on a methadone (or other substitute drug) prescription are considered 
to be ‘in treatment’ so are not included in these discharge figures.
The NTA record an individual as having been discharged ‘drug-free’ if they have 
“completed their treatment no longer dependent on their drug of misuse and 
are not using any other illegal drugs.”7 
As such, the definition provides a measure of drug users leaving treatment 
having achieved abstinence from the use of all illegal drugs. However, it does 
not account for clients discharged from treatment who no longer use their 
primary drug of choice but still use other substances. 
For example, an individual who leaves drug treatment no longer using heroin or 
crack cocaine but still uses cannabis recreationally is not considered ‘drug-free’ 
under the current definition. 
In recent years, the numbers of individuals discharged from treatment ‘drug-
free’ has increased. However, despite this rise, some within the drug sector and 
the media have highlighted that the actual number of individuals leaving ‘drug-
free’ represents only a small percentage of the total number of people engaged 
with treatment.
Individuals discharged from treatment drug-free 2004/05 to 2007/08
7 house of commons hansard: Written answers for 10 sep 2008 
http://www.publications.parliament.uk/pa/cm200708/cmhansrd/cm080910/text/80910w0026.htm
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Figure 5: Individuals discharged from treatment ‘drug-free’
2004/05 2005/06 2006/07 2007/08
no of individuals 
discharged 
from treatment 
completely ‘drug-
free’
3,632 4,559 5,829 7,324
percentage of 
total number of 
individuals in 
treatment
2.3% 2.6% 3.0% 3.6%
As of April 2009 a new coding system will be introduced which will define 
treatment completed ‘drug-free’ as “no longer using heroin and crack cocaine, 
or any other drugs for which treatment is being received”8.
A comparison between substitute prescribing and 
residential rehab
Questions of access, effectiveness and investment in abstinence-focused drug 
treatment and maintenance-based measures were central to The Great Debate. 
Discussions revolved around treatment modalities that embody each approach – 
the ‘drug-free’ ethos of residential rehabilitation and the most commonly used 
maintenance treatment, substitute prescribing.
The following pages briefly outline both approaches and detail key statistics 
comparing the levels of provision and estimated costs of each treatment.
What is the difference between rehab and substitute prescribing?
Residential rehab
Residential treatment programmes usually insist on residents being drug-
free on admission. In most cases this means the entrant has undergone 
detoxification before entry, although some programmes provide this facility on 
admission. Programmes usually last three to six months although some 12-step 
programmes (such as those associated with the Narcotics Anonymous model) 
can last 12 months.
Programmes vary widely in concept and practice, but generally attempt to 
provide group or individual support in a drug-free environment.
8 national treatment agency (october 2008), news release: New national statistics reveal more 
drug addicts in treatment – and they are staying the course 
http://www.nta.nhs.uk/media/media_releases/2008_media_releases/new_national_statistics_
reveal_more_drug_users_in_treatment_media_release_021008.aspx
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Substitute prescribing
These programmes look to prescribe heroin/opiate users with a substitute 
drug to stabilise or reduce an individual’s drug use in the long term. However, 
buprenorphine (brand name Subutex) is also used in some cases and 
diamorphine (pharmaceutical grade heroin) is prescribed to a fraction of clients.
Substitute prescribing interventions are usually delivered in community settings 
and take the form of maintenance or reduction programmes.
With methadone maintenance programmes the aim is not to eliminate drug 
use in the short term, but to stabilise the use by prescribing methadone as a 
substitute for heroin. The idea is to reduce the need for criminal activity, reliance 
on illicit drug markets and the harm caused by injecting and to stabilise the user 
with a view to them giving up drug use in the longer term.
Methadone reduction programmes usually take place in community settings 
and involve the prescribing of methadone to opiate users to control withdrawal 
symptoms. The aim is to gradually reduce the quantity prescribed until the user 
experiences no withdrawal symptoms and is drug-free.
Levels of provision of each modality
The NDTMS gathers data on the number of times a treatment modality was 
provided to individuals engaged with drug treatment. Year-on-year data shows 
that levels of substitute prescribing have risen steadily in recent years, while 
residential rehab levels have remained relatively stable.
However, when considering this data it should be noted that:
a) individuals can use a number of different treatment modalities during the 
year so these figures do not equate to a one individual = one treatment type, 
equation.
b) The NDTMS does not record the specific substitute drug prescribed and while 
the majority of clients will have received methadone, others may have received 
buprenorphine.
c) These figures are likely to be an underestimate of the level of residential rehab 
activity. Around one-third of providers of in England do not submit any returns 
to NDTMS, as independent voluntary sector providers of residential rehab are 
not obliged to provide data to the NTA.
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Number of treatment modalities provided 2004/05 to 2007/08
Figure 6: Number of treatment modalities provided 2004/05 to 2007/08
No. of treatment 
modalities provided
2004/05 2005/06 2006/07 2007/08
substitute prescribing 88,196 107,093 118,107 131,110
residential rehab 5,620 5,749 5,859 5,350
Cost comparison
In January 2009 Liberal Democrat Shadow Home Secretary Chris Huhne asked 
a Parliamentary Question about the average cost of a week’s drug treatment 
in residential rehabilitation services. Minister of State for Public Health Dawn 
Primarolo responded and said that, as of November 2008, the average cost of a 
week in a residential rehabilitation service was £500 per resident.9
Ms Primarolo said that the £500 per week figure is based on self-reported unit 
cost data gathered from the residential services who return data to the NTA. 
This is estimated to cover around 75% of all residential services in England 
and Wales and, according to the minister, “as such it does not represent a 
comprehensive or necessarily robust picture,” but was the most reliable figure 
available.
9 http://www.publications.parliament.uk/pa/cm200809/cmhansrd/cm090112/text/90112w0114.
htm#09011437007395
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In 2007, the Personal Social Services Research Unit estimated the average unit 
cost of voluntary sector residential rehabilitation for drugs or alcohol was £755 
per resident week.10
This figure was based on data collected in 1994/95 as part of the National 
Treatment Outcome Research Study (NTORS) with costs inflated to 2006/2007 
levels. The estimate included capital costs (e.g. buildings, equipment), revenue 
costs (e.g. staff salaries) and the use of the facility by the client.
The same report estimated the average cost of maintaining a drug user on a 
methadone treatment programme to be £55 per patient per week. Again, the 
figure was based on data from the NTORS research, adjusted to 2006/07 prices 
and included capital costs, revenue costs and prescription costs of methadone.
Treatment for drug  
or alcohol misuse
Average cost
voluntary sector residential 
rehabilitation
£500-755 per resident week*
methadone treatment programme £55 per patient week
*Based on the range between NTA data and NTORS estimates.
10 curtis l, netten a (2007): Unit Costs of Health and Social Care. university of kent: personal 
social services research unit; http://www.pssru.ac.uk/pdf/uc/uc2007/uc2007.pdf
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abstinence: Different definitions of the term according to perspective. 
However, commonly understood that when an individual refrains completely 
from using all drugs they are said to have achieved abstinence. An ‘abstinence-
based service’ offers a drug treatment programme that aims to help the 
individual stop using drugs for the rest of their lives.
detoxification, detox: The process by which a drug user withdraws from 
the effects of a drug. It usually refers to withdrawal in a safe environment (a 
detoxification/detox centre), with help on hand to minimise the unpleasant 
symptoms.
harm reduction: Describes activities and services that acknowledge the 
continued drug use of individuals, but seek to minimise the harm that such 
behaviour causes. The provision of clean needles for injecting drug users is one 
example.
methadone: A synthetic opioid prescribed to prevent people experiencing 
withdrawal effects from heroin and other opiate drugs. It lasts longer and does 
not provide the same ‘high’ or ‘rush’ as drugs like heroin.
methadone maintenance: An individual in receipt of prescriptions of 
methadone over a long period of time is said to be receiving ‘methadone 
maintenance’.
New Abstentionism: Coined by Mike Ashton in 2007 to refer to a growing 
movement in politics, media and the drug sector, arguing that the only goal 
of drug treatment should be complete abstinence from all drugs, including 
substitute drugs such as methadone.
overdose: The use of any drug in such quantities that acute adverse physical or 
mental effects occur. It can be deliberate or non-deliberate; lethal or non-lethal.
recovery: Often used to describe a vision and vocation for drug treatment that 
is less fixated on clinical indicators and quantitive targets, and more concerned 
with social (re)integration and qualitative outcomes.
relapse: When someone in drug treatment or who is abstinent returns to using 
illicit drugs.
Glossary4.2
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service user: Someone who uses drug treatment services.
substitute drugs: Drugs such as methadone or buprenorphine (Subutex), 
prescribed to drug users to help them manage withdrawal symptoms or to 
replace illicit drugs.
withdrawal: The body’s reaction to the sudden absence of a drug to which it 
has adapted. The effects can be stopped either by taking more of the drug, by 
managed detoxification or by letting the effects subside naturally (‘cold turkey’), 
which may take up to a week.
Abbreviations
ACMD  Advisory Council on the Misuse of Drugs
CAT  Community Addiction Team
DAT  Drug Action Team
EHRC  Equality and Human Rights Commission
NICE  National Institute for Clinical Excellence
NTA  National Treatment Agency for Substance Misuse
NTORS  National Treatment Outcomes Research Study
PTB  Pooled Treatment Budget
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